Defibrotide for the Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2 Pediatric Patients.
J Pediatric Infect Dis Soc
; 9(5): 622-625, 2020 Nov 10.
Article
in English
| MEDLINE | ID: covidwho-919277
ABSTRACT
The pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 infection is a severe complication of coronavirus disease 2019. Since impaired coagulation and thrombosis/endotheliitis are suspected pathomechanisms, we treated 2 patients with defibrotide, a profibrinolytic, antithrombotic, antiinflammatory oligonucleotide. Symptoms resolved during treatment. Moreover, coagulation parameters indicating hypofibrinolysis and complement activation normalized. The pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 infection is a severe complication of coronavirus disease 2019. Since impaired coagulation and thrombosis/endotheliitis are suspected pathomechanisms, 2 patients received defibrotide, a profibrinolytic, antithrombotic, antiinflammatory oligonucleotide. Symptoms resolved and hypofibrinolysis/complement activation normalized during treatment.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Polydeoxyribonucleotides
/
Platelet Aggregation Inhibitors
/
Coronavirus Infections
/
Systemic Inflammatory Response Syndrome
Type of study:
Case report
/
Diagnostic study
Topics:
Long Covid
Limits:
Adolescent
/
Child
/
Female
/
Humans
Language:
English
Journal:
J Pediatric Infect Dis Soc
Year:
2020
Document Type:
Article
Affiliation country:
Jpids
Similar
MEDLINE
...
LILACS
LIS